BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 35012916)

  • 1. [Screening of drugs that selectively inhibit uveal melanoma cells with SF3B1 mutations].
    Luo X; Ren C; Liu X; Zhang G; Huang S; Yu L; Li Y
    Nan Fang Yi Ke Da Xue Xue Bao; 2021 Dec; 41(12):1835-1842. PubMed ID: 35012916
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SF3B1 mutations are associated with alternative splicing in uveal melanoma.
    Furney SJ; Pedersen M; Gentien D; Dumont AG; Rapinat A; Desjardins L; Turajlic S; Piperno-Neumann S; de la Grange P; Roman-Roman S; Stern MH; Marais R
    Cancer Discov; 2013 Oct; 3(10):1122-1129. PubMed ID: 23861464
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutations of GNAQ, GNA11, SF3B1, EIF1AX, PLCB4 and CYSLTR in Uveal Melanoma in Chinese Patients.
    Hou C; Xiao L; Ren X; Tang F; Guo B; Zeng W; Liang C; Yan N
    Ophthalmic Res; 2020; 63(3):358-368. PubMed ID: 31614358
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Co-occurrence of BAP1 and SF3B1 mutations in uveal melanoma induces cellular senescence.
    Yu L; Zhou D; Zhang G; Ren Z; Luo X; Liu P; Plouffe SW; Meng Z; Moroishi T; Li Y; Zhang Y; Brown JH; Liu S; Guan KL
    Mol Oncol; 2022 Feb; 16(3):607-629. PubMed ID: 34706158
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Splicing Patterns in
    Bigot J; Lalanne AI; Lucibello F; Gueguen P; Houy A; Dayot S; Ganier O; Gilet J; Tosello J; Nemati F; Pierron G; Waterfall JJ; Barnhill R; Gardrat S; Piperno-Neumann S; Popova T; Masson V; Loew D; Mariani P; Cassoux N; Amigorena S; Rodrigues M; Alsafadi S; Stern MH; Lantz O
    Cancer Discov; 2021 Aug; 11(8):1938-1951. PubMed ID: 33811047
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recurrent mutations at codon 625 of the splicing factor SF3B1 in uveal melanoma.
    Harbour JW; Roberson ED; Anbunathan H; Onken MD; Worley LA; Bowcock AM
    Nat Genet; 2013 Feb; 45(2):133-5. PubMed ID: 23313955
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cancer-associated SF3B1 mutations affect alternative splicing by promoting alternative branchpoint usage.
    Alsafadi S; Houy A; Battistella A; Popova T; Wassef M; Henry E; Tirode F; Constantinou A; Piperno-Neumann S; Roman-Roman S; Dutertre M; Stern MH
    Nat Commun; 2016 Feb; 7():10615. PubMed ID: 26842708
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exome sequencing identifies recurrent somatic mutations in EIF1AX and SF3B1 in uveal melanoma with disomy 3.
    Martin M; Maßhöfer L; Temming P; Rahmann S; Metz C; Bornfeld N; van de Nes J; Klein-Hitpass L; Hinnebusch AG; Horsthemke B; Lohmann DR; Zeschnigk M
    Nat Genet; 2013 Aug; 45(8):933-6. PubMed ID: 23793026
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-Read Sequencing Reveals Alternative Splicing-Driven, Shared Immunogenic Neoepitopes Regardless of SF3B1 Status in Uveal Melanoma.
    Yao T; Zhang Z; Li Q; Huang R; Hong Y; Li C; Zhang F; Huang Y; Fang Y; Cao Q; Jin X; Li C; Wang Z; Lin XJ; Li L; Wei W; Wang Z; Shen J
    Cancer Immunol Res; 2023 Dec; 11(12):1671-1687. PubMed ID: 37756564
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Uveal Melanomas with SF3B1 Mutations: A Distinct Subclass Associated with Late-Onset Metastases.
    Yavuzyigitoglu S; Koopmans AE; Verdijk RM; Vaarwater J; Eussen B; van Bodegom A; Paridaens D; Kiliç E; de Klein A;
    Ophthalmology; 2016 May; 123(5):1118-28. PubMed ID: 26923342
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SF3B1 mutations constitute a novel therapeutic target in breast cancer.
    Maguire SL; Leonidou A; Wai P; Marchiò C; Ng CK; Sapino A; Salomon AV; Reis-Filho JS; Weigelt B; Natrajan RC
    J Pathol; 2015 Mar; 235(4):571-80. PubMed ID: 25424858
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of Uveal Melanoma Metastatic Rate With Stochastic Mutation Rate and Type of Mutation.
    Szalai E; Jiang Y; van Poppelen NM; Jager MJ; de Klein A; Kilic E; Grossniklaus HE
    JAMA Ophthalmol; 2018 Oct; 136(10):1115-1120. PubMed ID: 30073324
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The SF3B1
    Guo J; Li C; Fang Q; Liu Y; Wang D; Chen Y; Xie W; Zhang Y
    J Exp Clin Cancer Res; 2022 Jan; 41(1):26. PubMed ID: 35039052
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Spliceosome Mutations in Uveal Melanoma.
    Nguyen JQN; Drabarek W; Yavuzyigitoglu S; Medico Salsench E; Verdijk RM; Naus NC; de Klein A; Kiliç E; Brosens E
    Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33333932
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bioinformatics analysis of GNAQ, GNA11, BAP1, SF3B1,SRSF2, EIF1AX, PLCB4, and CYSLTR2 genes and their role in the pathogenesis of Uveal Melanoma.
    Akin-Bali DF
    Ophthalmic Genet; 2021 Dec; 42(6):732-743. PubMed ID: 34353217
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dual Inhibition of Histone Deacetylases and the Mechanistic Target of Rapamycin Promotes Apoptosis in Cell Line Models of Uveal Melanoma.
    Patel RP; Thomas JR; Curt KM; Fitzsimmons CM; Batista PJ; Bates SE; Gottesman MM; Robey RW
    Invest Ophthalmol Vis Sci; 2021 Sep; 62(12):16. PubMed ID: 34533562
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SF3B1 and EIF1AX mutations occur in primary leptomeningeal melanocytic neoplasms; yet another similarity to uveal melanomas.
    Küsters-Vandevelde HV; Creytens D; van Engen-van Grunsven AC; Jeunink M; Winnepenninckx V; Groenen PJ; Küsters B; Wesseling P; Blokx WA; Prinsen CF
    Acta Neuropathol Commun; 2016 Jan; 4():5. PubMed ID: 26769193
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Driver Mutations in Uveal Melanoma: Associations With Gene Expression Profile and Patient Outcomes.
    Decatur CL; Ong E; Garg N; Anbunathan H; Bowcock AM; Field MG; Harbour JW
    JAMA Ophthalmol; 2016 Jul; 134(7):728-33. PubMed ID: 27123562
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutation frequencies of GNAQ, GNA11, BAP1, SF3B1, EIF1AX and TERT in uveal melanoma: detection of an activating mutation in the TERT gene promoter in a single case of uveal melanoma.
    Dono M; Angelini G; Cecconi M; Amaro A; Esposito AI; Mirisola V; Maric I; Lanza F; Nasciuti F; Viaggi S; Gualco M; Bandelloni R; Truini M; Coviello DA; Zupo S; Mosci C; Pfeffer U
    Br J Cancer; 2014 Feb; 110(4):1058-65. PubMed ID: 24423917
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Altered splicing and cytoplasmic levels of tRNA synthetases in SF3B1-mutant myelodysplastic syndromes as a therapeutic vulnerability.
    Liberante FG; Lappin K; Barros EM; Vohhodina J; Grebien F; Savage KI; Mills KI
    Sci Rep; 2019 Feb; 9(1):2678. PubMed ID: 30804405
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.